OM vs FMS vs DVA vs BAX

For growth investors, DaVita Inc.

(DVA) is the stronger pick with 6. 5% revenue growth year-over-year, versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11. 0x trailing P/E (10. 9x forward), making it the more compelling value choice. Analysts rate Fresenius Medical Care AG & Co. KGaA (FMS) a "Hold" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Fresenius Medical Care AG & Co.

KGaA (FMS) is the cheapest at 11. 0x versus DaVita Inc. at 20. 6x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: DaVita Inc. wins at 1. 64x versus Fresenius Medical Care AG & Co. KGaA's 2. 13x — a reasonable growth-adjusted valuation.

Over the past 5 years, DaVita Inc.

(DVA) delivered a total return of +54. 8%, compared to -99. 4% for Outset Medical, Inc. (OM). Over 10 years, the gap is even starker: DVA returned +161. 2% versus OM's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DaVita Inc.

(DVA) is the lower-risk stock at 0. 25β versus Outset Medical, Inc. 's 2. 15β — meaning OM is approximately 768% more volatile than DVA relative to the S&P 500. On balance sheet safety, Fresenius Medical Care AG & Co. KGaA (FMS) carries a lower debt/equity ratio of 76% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DaVita Inc.

(DVA) is pulling ahead at 6. 5% versus 1. 5% for Fresenius Medical Care AG & Co. KGaA (FMS). On earnings-per-share growth, the picture is similar: Outset Medical, Inc. grew EPS 85. 5% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, DVA leads at 5. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DaVita Inc.

(DVA) is the more profitable company, earning 5. 5% net margin versus -68. 3% for Outset Medical, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DVA leads at 14. 7% versus -55. 8% for OM. At the gross margin level — before operating expenses — OM leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, DaVita Inc. (DVA) is the more undervalued stock at a PEG of 1. 64x versus Fresenius Medical Care AG & Co. KGaA's 2. 13x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 4x forward P/E versus 13. 6x for DaVita Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FMS: 29. 4% to $28. 00.

In this comparison, BAX (3.

9% yield), FMS (3. 8% yield) pay a dividend. OM, DVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Fresenius Medical Care AG & Co.

KGaA (FMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 50), 3. 8% yield). Outset Medical, Inc. (OM) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FMS: -34. 2%, OM: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OM is a small-cap quality compounder stock; FMS is a mid-cap deep-value stock; DVA is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock. FMS, BAX pay a dividend while OM, DVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.